PAR-5359, a well-balanced PPARα/γ dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo-Reference-Cited by-同舟云学术

PAR-5359, a well-balanced PPARα/γ dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo

Published:2008-10 Issue:1-3 Volume:595 Page:119-125
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Kim Mi-Kyung,Chae Yu Na,Son Moon Ho,Kim Soon Hoe,Kim Jin Kwan,Moon Ho Sang,Park Chan Sun,Bae Myung-Ho,Kim Eunkyung,Han Taedong,Choi Hyun-ho,Shin Young Ah,Ahn Byung-Nak,Lee Chun Ho,Lim Joong In,Shin Chang Yell

Funder

Ministry of Health and Welfare

Publisher

Elsevier BV

Subject

Pharmacology

Reference37 articles.

1. PPAR dual agonists: are they opening Pandora's Box?;Balakumar;Pharmacol. Res.,2007

2. Adiponectin, obesity and atherosclerosis;Behre;Scand. J. Clin. Lab. Invest.,2007

3. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat;Braissant;Endocrinology,1996

4. Differential activation of adipogenesis by multiple PPAR isoforms;Brun;Genes Dev.,1996

5. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice;Cha;Diabetes,2007

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Living Organoid Biobank of Crohn’s Disease Patients Reveals Molecular Subtypes for Personalized Therapeutics;2023-03-13

2. Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease;Communications Biology;2022-03-14

3. Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease;PPAR Research;2022-02-18

4. Aerobic exercise modulates noncoding RNA network upstream of FNDC5 in the Gastrocnemius muscle of high-fat-diet-induced obese mice;Journal of Physiology and Biochemistry;2021-08-18

5. Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetes;Expert Opinion on Pharmacotherapy;2021-08-05